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Background: Fluid accumulation frequently coexists with acute kidney injury (AKI) 
and is associated with increased risk for AKI progression and mortality. Among septic 
shock patients, restricted use of resuscitation fluid has been reported to reduce the 
risk of worsening of AKI. Restrictive fluid therapy, however, has not been studied in 
the setting of established AKI. Here, we present the protocol and statistical analy-
sis plan of the REstricted fluid therapy VERsus Standard trEatment in Acute Kidney 
Injury—the REVERSE-AKI trial that compares a restrictive fluid therapy regimen to 
standard therapy in critically ill patients with AKI.
Methods: REVERSE-AKI is an investigator-initiated, multinational, open-label, ran-
domized, controlled, feasibility pilot trial conducted in seven ICUs in five countries. 
We aim to randomize 100 critically ill patients with AKI to a restrictive fluid treat-
ment regimen vs standard management. In the restrictive fluid therapy regimen, the 
daily fluid balance target is neutral or negative. The primary outcome is the cumula-
tive fluid balance assessed after 72 hours from randomization. Secondary outcomes 
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1  | INTRODUC TION
Acute kidney injury (AKI) is a frequent syndrome during critical 
illness affecting approximately 40%-57% patients in the inten-
sive care unit (ICU).1,2 It carries an increased risk for adverse out-
comes such as mortality, prolonged hospital stay, development of 
chronic kidney disease (CKD), and increased health-care costs.1-3 
Currently, the treatment of AKI is supportive, and approximately 
one fifth of patients with severe AKI require renal replacement 
therapy (RRT).1,2
The rationale to administer fluid in AKI has been the desire to 
increase renal blood flow and perfusion pressure by increasing car-
diac output and blood pressure.3,4 However, patients with AKI are 
prone to develop fluid overload.5 Excessive fluid administration has 
also been associated with new development of AKI and progression 
of AKI.6,7 The potential mechanisms include increased intra-abdomi-
nal pressure, renal congestion, and renal subcapsular edema leading 
to raised intrarenal pressure.8 Multiple observational studies have 
also shown an association between fluid accumulation and increased 
mortality.5,9-11
Restricting fluid input among patients with AKI might be 
beneficial in terms of reducing edema formation, which could 
potentially improve organ function and prevent further injury, 
and subsequently lead to increased survival. A feasibility study 
in septic shock patients comparing restrictive vs standard fluid 
resuscitation reported a lower risk of worsening of AKI in the 
restrictive group.12 Trials in other subgroups of critically ill pa-
tients have demonstrated that restricting fluid input after the 
initial resuscitation was safe.12-14 A large trial among patients 
undergoing major abdominal surgery comparing restrictive vs 
standard fluid therapy for 24 hours intra- and post-operatively 
did not report difference in the disability-free 1-year survival, 
whereas the risk of AKI was increased among those with restric-
tive fluid therapy.15 The need for further studies specifically in 
critically ill patients with AKI has been identified as a research 
priority.16,17
Our aim is to conduct a multinational, open-label, randomized, 
controlled, feasibility pilot trial comparing a restrictive fluid treat-
ment regimen to standard treatment among patients with AKI to 
study the feasibility of such intervention in terms of separation 
of groups, safety, and compliance. We hypothesize that the pro-
posed restricted fluid treatment regimen will lead to 1200 mL 
lower cumulative fluid balance at 72 hours post-randomization. 
Assessing the feasibility of this intervention is necessary before 
larger trials with patient-centered outcomes as primary outcomes 
can be conducted.
2  | METHODS
2.1 | Trial design and setting
The REVERSE-AKI trial is an investigator-initiated, multicenter, open, 
randomized controlled pilot study. Helsinki University Hospital 
(in Helsinki Finland) is the coordinating center. Adult ICUs from 
Australia (Austin Hospital, Canberra Hospital), Belgium (University 
Hospital of Ghent), Switzerland (Lausanne University Hospital), and 
the UK (Guy's and St Thomas Hospital, The Royal London Hospital) 
will participate.
2.2 | Trial registration
The REVERSE-AKI trial was registered with clinicaltrials.gov (identi-
fier NCT03251131) on 16 August 2017.
2.3 | Trial conduct
The study protocol was prepared as outlined in the Standard Protocol 
Items: Recommendations for Interventional Trials (SPIRIT) guide-
lines.18 The study will be conducted according to the Declaration of 
Helsinki, the principles of Good Clinical Practice, and in accordance 
with local legislation in participating countries.
2.4 | Randomization
Eligible patients who fulfill all inclusion criteria and have no exclusion 
criteria will be randomized using web-based allocation concealment 
based on a computer-based algorithm created by an independent 
statistician. Randomization will be stratified according to (a) the 
presence of clinical signs of fluid accumulation (defined by peripheral 
pitting edema and/or positive fluid balance with P/F ratio less than 
200 mmHg) and (b) severity of AKI (stage 1 vs stage 2 or 3 as de-
fined by the Kidney Disease: Improving Global Outcomes (KDIGO) 
criteria16; detailed definition presented in the Supplement Data S1). 
Permutated blocks of varying sizes from 2 to 4 will be used.
include safety, feasibility, duration, and severity of AKI, and outcome at 90 days (mor-
tality and dialysis dependence).
Conclusions: This is the first multinational trial investigating the feasibility and safety 
of a restrictive fluid therapy regimen in critically ill patients with AKI.
Trial registration: clinical.trials.gov NCT03251131.
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2.5 | Blinding
The trial intervention will not be blinded for investigators, ICU person-
nel, or patients due to its nature. The statistician conducting the data 
analysis will be masked for the group allocation. We will compile an ab-
stract of the study results prior to becoming aware of the group alloca-
tion, which will be included in the appendix of the original publication.
2.6 | Inclusion and exclusion criteria
All admissions to ICU will be initially screened. The detailed defi-
nitions of inclusion and exclusion criteria are presented in the 
Supplement Data S1.
2.6.1 | Inclusion criteria
1. 18 years or older and admitted to critical care with an arterial 
line in place
2. The patient has been in critical care for at least 12 hours but no 
more than 72 hours
3. The patient has AKI but is not receiving acute RRT:
AKI is defined by the following criteria:
a. Increase in serum creatinine over 1.5 times above baseline 
without a decline of 27 µmol/L or more from the last preced-
ing measurement (at least 12 hours apart)
AND/OR
b. Overall urine output less than 0.5 mL kg−1 h−1 (or 6 mL/kg) 
for the previous 12 hours (with urine catheter in place for the 
period)
4. The patient is judged by the treating clinician not to be intravascu-
larly hypovolemic
5. The patient is likely to remain in critical care for 48 hours after 
randomization
2.6.2 | Exclusion criteria
 1. Active bleeding necessitating transfusion
 2. Maintenance fluid therapy is necessary due to diabetic ketoaci-
dosis, non-ketotic coma, severe burns, or other clinical reason 
determined by the medical staff
 3. Need for RRT due to intoxication of a dialyzable toxin
 4. Commencement of RRT is expected in the next 6 hours
 5. On chronic RRT (maintenance dialysis or renal transplant)
 6. Presence or a strong clinical suspicion of parenchymal AKI (eg, 
glomerulonephritis, vasculitis, acute interstitial nephritis) or 
post-renal obstruction
 7. Severe hyponatremia (Na <125 mmol/L) or hypernatremia 
(Na >155 mmol/L)
 8. Need for extracorporeal membrane oxygenation or molecular 
absorbent recirculating system
 9. Pregnant or lactating
 10. Patients who are not to receive full active treatment
 11. No baseline creatinine available
 12. Lack of consent
 13. The patient has been enrolled in another trial where co-enroll-
ment is not feasible
2.7 | Trial interventions
Table 1 presents the timeline of eligibility, randomization, and study 
interventions. The intervention period relates to the first 7 days after 
randomization as long as the patient is still in the critical care unit.
2.7.1 | Experimental arm (restricted fluid 
management)
Targets from the time of randomization.
1. Total daily fluid input is restricted to only medications and 
nutritional fluids (enteral or parenteral) and blood products (if 
clinically necessary). No maintenance IV fluids will be admin-
istered. Fluid bolus therapy can be given if clinically deemed 
necessary.
2. Maintenance fluid is only acceptable if enteral nutrition is not tol-
erated and parenteral nutrition is contraindicated.
3. Fluid output (with unrestricted use of diuretics) to match input 
whenever possible and to achieve a fluid balance which is prefer-
ably negative and always less than +300 mL/d
4. If such a fluid balance target cannot be achieved, RRT is consid-
ered to remove the required fluid. Commencing RRT is not man-
dated in the trial.
5. If continuous RRT is not considered clinically desirable, ac-
ceptance of a less than targeted fluid balance temporarily up 
to +900 mL provided it lasts only 24 hours.
Fluid balance is calculated by subtracting total fluid output (urine 
output, losses to drains, losses from gastrointestinal tract, and ultra-
filtration by RRT) from total fluid input (intravenous and per oral). 
Insensible losses are not considered.
2.7.2 | Standard group
All aspects of fluid therapy will be at the discretion of the treating 
clinical team.
2.7.3 | Concomitant treatment
All other aspects of care will be according to the local practices and 
treating clinicians’ judgment. Fluid removal (either using diuretics or 
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TA B L E  1   Overview of the schedule of enrollment, interventions, and assessments according to the SPIRIT 2013 statement
Enrollment Allocation Post-allocation (days from randomization) 
ICU 
admission  
ICU stay at 
least 12 but 
no more than 
72 hrs 
Time of 
randomizati
on 
0-2 3 4-7 8-14 Day 90 
Enrollment:
Timepoint
 
 
      
Initial eligibility screen X 
 
      
Full eligibility screen  
X 
      
Informed consent   
 
      
Allocation  
 
X      
Interventions:  
 
      
[Restrictive fluid 
therapy]  
 
      
[Standard fluid 
therapy]  
 
      
Assessments:  
 
      
[Baseline 
characteristics, 
chronic comorbidities, 
admission diagnosis, 
severity scores, organ 
support]
X X X      
[Presence of 
stratification variables: 
fluid overload and 
severity of AKI]
 
 
X      
[Fluid therapy, fluid 
output]a
 
 
 X X X   
Cumulative fluid 
balance  
 
 
 X Xb X   
[Safety events]a
 
 
 X X X   
[Organ support, 
severity of AKI]a 
 
       
[Need for RRT]
 
  
     
[Mortality]
 
 
      
Abbreviations: AKI; acute kidney injury, RRT; renal replacement therapy.
aWhile in the ICU. 
bPrimary outcome. 
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ultrafiltration) will not be controlled. Initiation of RRT will be accord-
ing to the clinician's judgment.
2.8 | Outcome measures
2.8.1 | Primary outcome measure
Cumulative fluid balance at first 72 hours after randomization is 
the primary outcome of the study. The time point chosen to as-
sess the outcome was justified by data from two large cohort stud-
ies1,2 that have reported the median ICU stay of AKI patients to 
be 3.7-6 days.
2.8.2 | Secondary outcome measures
1. Duration of AKI in days defined by the KDIGO creatinine and 
urine output criteria (truncated at ICU discharge or 14 days, 
whichever comes first)
2. Number of patients requiring RRT (truncated at 14 days)
3. Cumulative fluid balance at
(i) 24 hours after randomization
(ii) at ICU discharge (or truncated at 7 days if ICU stay exceeds 
7 days)
4. Cumulative dose of diuretics during the intervention period (while 
in the ICU, maximum of 7 days) adjusted for the duration of obser-
vation period
Duration of AKI is a secondary outcome of the trial. We will test 
the feasibility of recording it, the potential challenges as a result 
of using creatinine-based diagnostics (possible dilution and subse-
quently lower incidence in the standard group), and the potentially 
increased use of diuretics in the interventional arm that could con-
found the assessment of urine output criterion.19
2.8.3 | Exploratory outcomes
1. Mechanical ventilation-free and days alive (truncated at 14 days)
2. Vasopressor-free days and alive (truncated at 14 days)
3. ICU-free days and alive (truncated at 14 days)
4. RRT-free days and alive (90 days)
5. 90-day dialysis dependence
6. 90-day mortality
2.8.4 | Safety and feasibility outcomes
1. Number of patients with one or more (serious) adverse events 
and reactions in both arms (detailed definitions are provided 
in the Supplement Data S1)
a. Ventricular tachycardia/fibrillation
b. New onset of atrial fibrillation requiring medication/
defibrillation
c. Ischemic events
d. Radiologically diagnosed pulmonary edema
e. Adverse events related to RRT and diuretics use
f. Frequency of hypokalemia (serum K <3.5 mmol/L)
g. Frequency of hypomagnesemia (serum Mg <0.8 mmol/L)
h. Frequency of serum pH >7.5
i. Other
2. Screened vs recruited patients’ ratio
3. Recruitment rate (patients/center/month)
4. Protocol compliance (number of patients with protocol violations 
in both arms)
2.9 | Data collection
Trained research personnel will perform the data collection using an 
electronic platform (Absolute imaginary Software Ltd). Data about 
baseline characteristics, ICU severity scores and admission diag-
noses, daily fluid input and output, and need for organ supportive 
therapies will be collected. Trial follow-up regarding need for RRT 
and vital status will last until 90 days. The detailed list of collected 
data items and schedule for collected plasma samples are provided 
in the Supplement Data S1.
2.10 | Statistical analysis
2.10.1 | General analytical principles
Statistical analyses will be performed on the intention-to-treat (ITT) 
population defined as all randomized subjects with consent to use 
data in the analysis. The conclusions of the analysis will be based on 
the ITT analysis.
A sensitivity analysis will be conducted in the per-protocol popu-
lation, defined as the ITT population after exclusion of subjects who 
experienced one or several protocol violations or stayed less than 
48 hours in the ICU post-randomization.
Assumption of normality will be checked by Shapiro-Wilk test for 
continuous variables. Statistical significance will be set to 0.05 and 
two-sided P-values will be reported.
2.10.2 | Primary outcome
The primary outcome between restrictive fluid treatment regimen and 
standard groups will be adjusted for the two stratification variables (pres-
ence of fluid accumulation and severity of AKI) using two-tailed general 
linear or median regression and depending on distribution, estimated 
means with standard deviation (SD) or medians with interquartile range 
(IQR) with a measure of distribution will be reported. Additionally, we will 
calculate the difference with 95% confidence intervals (CIs) between the 
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groups using mean or median regression. We will report the crude cumu-
lative fluid balance in both groups and compare them using appropriate 
test depending on the variable distribution.
2.10.3 | Secondary and exploratory outcomes
All secondary and exploratory outcome variables will be adjusted 
for the two stratification variables either with two-tailed logistic re-
gression (dichotomous outcomes, given that the number of observed 
outcomes will permit adjustment) or a linear model (continuous 
outcome variables, mean or median regression model). Risk ratios 
with 95% CIs or difference in means/median with 95% CIs will be re-
ported. Additionally, we will report crude outcomes with risk ratios 
for dichotomous outcomes and absolute differences with 95% CIs 
for continuous outcomes.
2.10.4 | Other variables
All categorical data will be compared using Chi-square test and con-
tinuous variables using Mann-Whitney U test or Student's t test de-
pending on normal distribution.
2.10.5 | Missing data
Some patients may be discharged from the ICU before completing 
the 72 hours post-randomization phase in full. For these patients, 
the balance available at ICU discharge will be used in the analy-
ses. Regarding other outcome variables, we expect the number 
of missing data to be low and therefore, no imputation is planned. 
Regarding baseline characteristics and data for daily SOFA scores, if 
the number of missing observations is less than 5%, we will not im-
pute data. In case the number of missing data exceeds 5%, an appro-
priate multiple imputation strategy (ie, missing at random or missing 
completely at random) will be used.
2.11 | Sample size
Due to the lack of previous interventional trials in the field, it is dif-
ficult to estimate the meaningful difference in the primary outcome. 
Using unpublished data from the FINNAKI study1 cohort including 
480 patients with AKI defined as the trial inclusion criteria and ex-
cluding patients who commenced RRT within 24 hours of ICU admis-
sion, we found the median cumulative fluid balance at 72 hours to be 
2653 mL (interquartile range from 427 mL to 5918 mL). Cumulative 
fluid balance (in liters) associated with an increased risk for 90-day 
mortality with an odds ratio of 1.09 (95% CI 1.04-1.13), P < .001. 
Thus, we assume that a decrease in fluid balance of 1.2 L could ul-
timately translate into meaningful differences in patient-centered 
outcomes.
Therefore, we aim to randomize 100 patients (50 in each group) 
to have a >80% power to detect a difference in fluid balance at 
72 hours after randomization of +2700 mL in the standard group vs 
+1500 ml in the fluid restrictive group (both with a SD of 2000 mL) 
at an alpha error of 0.05. This would represent a difference of 
400 mL/d, which appears achievable.
Power calculations for secondary or exploratory outcomes were 
not done.
2.12 | Pre-planned subgroup analyses
No subgroup analyses will be conducted.
2.13 | Trial profile
We will report the flow of trial participants according to the 
CONSORT statement.20
2.14 | Data monitoring and safety committee
No data and safety monitoring committee (DSMB) will be formed 
as the trial is a low-risk pilot trial. Informed consents, inclusion and 
exclusion criteria, and collected data will be monitored.
2.15 | Interim analyses
No interim analyses will be conducted.
3  | DISCUSSION
International expert panels identified the investigation of restrict-
ing fluid therapy among patients with AKI as a research priority.16,17 
Trials in acute respiratory distress syndome (ARDS) and septic shock 
patients using various protocols to study restrictive fluid therapy in 
comparison to standard12 or liberal fluid therapy13,14 have shown that 
it is safe in critically ill patients. However, data in critically ill patients 
with AKI are missing. Our trial will provide data about the safety, 
feasibility, and efficacy of a restrictive fluid regimen in patients with 
AKI. The results will help to plan larger randomized controlled trials 
studying patient-centered outcomes as primary endpoints.
The strengths of this trial include its multinational design. 
Moreover, the restrictive fluid regimen is planned to target the fluid 
balance, and not just specifically restricting fluid input. This flexi-
ble approach allows the treating clinicians to tailor the fluid therapy 
individually and this strategy will probably lead to a more clinically 
meaningful approach than solely restricting only fluid input or en-
hancing fluid output. Finally, we will enroll patients with AKI of 
different severity (excluding only those already receiving RRT or in 
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whom commencing RRT is imminent), which will increase the gener-
alizability of the results.
Our trial has some limitations, too. First, due to the nature of 
the intervention, the patient, clinical team, or the investigators are 
not blinded. However, the trial statistician will be blinded to group 
allocation. Second, management of fluid balance in standard therapy 
arm will be according to the local practices of each participating cen-
ter, and potentially these may vary between geographical regions. 
Additionally, we will enroll patients after the initial fluid resuscitation 
has been completed. Thus, after stabilization, the clinical treatment 
goals typically include fluid removal, which means targeting negative 
fluid balances also in the standard arm.21 Moreover, the sample size 
calculation was based on data from a Finnish observational study, 
during which rather liberal fluid practices were in place.1 Therefore, 
it is possible that large variation in fluid treatment practices across 
centers and negative balance targets also in the standard arm hinder 
observing a significant separation between groups in the primary 
outcome.
In conclusion, the multinational REVERSE-AKI pilot trial will 
investigate the safety, feasibility, and efficacy of a restrictive fluid 
therapy regimen compared to standard therapy. Its results will help 
to plan larger randomized trials to be conducted in the future.
4  | ETHIC AL CONSIDER ATIONS AND 
CONSENT TO PARTICIPATE
The approval of local ethics committee has been obtained prior to 
commencing study screening in all participating countries. The con-
sent policy follows local requirements. In some settings, a deferred 
consent has been approved with an informed, written consent ob-
tained as soon as possible.
5  | DATA SHARING STATEMENT
The de-identified trial data set will be published as a supplement to 
the original publication.
6  | DISSEMINATION
Results of the study will be submitted in a peer-reviewed medical 
journal regardless of the results.
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